Full-Time

Senior Compliance Specialist

Updated on 12/21/2024

Neurocrine Biosciences

Neurocrine Biosciences

1,001-5,000 employees

Healthcare

Compensation Overview

$101.2k - $146.6kAnnually

+ Annual Bonus + Equity Incentive Program

Mid, Senior

San Diego, CA, USA

Requires in-office presence in San Diego for 3+ days per week when not traveling.

Category
Risk & Compliance
Legal & Compliance
Required Skills
Data Analysis
Requirements
  • Bachelors degree or equivalent and 4+ years of relevant experience in the biotech/pharmaceutical or medical device industry
  • Compliance and Ethics Professional Certification preferred
  • Understanding of healthcare compliance laws, regulations, and industry codes applicable to a pharmaceutical company with a commercial product, including federal Anti-kickback Statute, FDA promotional regulations, federal and state spend transparency laws and the PhRMA Code
  • Strong ability to use word processing and presentation software to prepare documents and training, and to use spreadsheet and statistical analysis software to store, manipulate, analyze and present data
  • Ability to manage multiple projects, meet deadlines, and adjust to changes in priorities
  • Strong organizational skills and attention to detail
  • Strong data analytics skills
  • Strong critical thinking and problem-solving skills using creativity and sound judgment
  • Strong written, verbal, and listening skills
  • Strong teamwork and interdisciplinary collaboration skills
  • Flexible to travel (minimum 40% of time)
  • In-office 3+ days per week when not traveling
Responsibilities
  • Provide sound compliance guidance consistent with applicable laws, regulations and Neurocrine policies
  • Conduct field and desk monitoring to ensure compliance with applicable laws, regulations, and Neurocrine policies
  • Create and deliver live and recorded trainings on Ethics & Compliance
  • Manage projects and support compliance initiatives
  • Assist with internal investigations, spend transparency, and other projects as needed
  • Other duties as assigned or required
Neurocrine Biosciences

Neurocrine Biosciences

View

Company Stage

IPO

Total Funding

N/A

Headquarters

San Diego, California

Founded

1992

Growth & Insights
Headcount

6 month growth

0%

1 year growth

0%

2 year growth

0%
Simplify Jobs

Simplify's Take

What believers are saying

  • FDA approval of CRENESSITY highlights innovation in rare disease treatment.
  • Partnership with PANTHERx Rare ensures specialized distribution and patient support for CRENESSITY.
  • Growing focus on rare disease treatments supports Neurocrine's strategic direction.

What critics are saying

  • Competition from alternative CAH treatments could impact CRENESSITY's market share.
  • Reliance on PANTHERx Rare for distribution poses a risk if disruptions occur.
  • Potential unidentified side effects of CRENESSITY could lead to regulatory scrutiny.

What makes Neurocrine Biosciences unique

  • CRENESSITY is the first non-steroidal treatment for classic congenital adrenal hyperplasia.
  • Neurocrine's CRENESSITY is a first-in-class CRF1 receptor antagonist for CAH.
  • CRENESSITY allows reduced glucocorticoid doses while maintaining androgen control in CAH patients.

Help us improve and share your feedback! Did you find this helpful?